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Abstract   1 
Lysergic acid diethylamide (LSD) is a widely used recreational drug. The aim of the present 2 
study is to develop a quantitative turboflow LC-MS/MS method that can be used for rapid 3 
quantification of LSD and its main metabolite 2-oxo-3-hydroxy LSD (O-H-LSD) in serum and 4 
urine in emergency toxicological cases without time consuming extraction steps. The method was 5 
developed on a ion-trap LC-MS/MS instrument coupled to a turbulent-flow extraction system. 6 
The validation data showed no significant matrix effects and no ion suppression has been 7 
observed in serum and urine. Mean intraday accuracy and precision for LSD were 101% and 8 
6.84%, in urine samples and 97.40% and 5.89% in serum, respectively. For O-H-LSD the 9 
respective values were 97.50% and 4.99% in urine and 107% and 4.70% in serum. Mean interday 10 
accuracy and precision for LSD were 100% and 8.26% in urine and 101% and 6.56% in serum. 11 
For O-H-LSD the respective values were 101% and 8.11% in urine and 99.8% and 8.35%, in 12 
serum. The lower limit of quantification for LSD was determined to be 0.1 ng/ml. LSD 13 
concentrations in serum were expected to be up to 8 ng/ml. 2-oxo-3-hydroxy LSD concentrations 14 
in urine up to 250 ng/ml. 15 
 The new method was accurate and precise in the range of expected serum and urine 16 
concentrations in patients with a suspected LSD intoxication. Until now the method has been 17 
applied in five cases with suspected LSD intoxication where the intake of the drug has been 18 
verified four times with LSD concentrations in serum in the range of 1.80 – 14.70 ng/ml and once 19 
with a LSD concentration of 1.25ng/ml in urine. In serum of two patients the O-H-LSD 20 
concentration was determined to be 0.99 ng/ml and 0.45 ng/ml. In the urine of a third patient the 21 
O-H-LSD concentration was 9.70 ng/ml. 22 
 23 
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Introduction 2 
Lysergic acid diethylamide (LSD) is a psychoactive substance changing the state of 3 
consciousness and perception. Its psychedelic effects made it popular as recreational drug, 4 
especially in the early 70’s, but still today LSD is widely used [1]. Additionally, LSD (200 µg) 5 
has also recently been used in a clinical study as adjunct to psychotherapy [2]. LSD is one of the 6 
most potent psychotropic drugs and is used in low doses. Typical recreational doses of LSD 7 
range from only 25 to 200 µg with long lasting, dose-dependent psychotropic effects [1]. Hence, 8 
low blood and urine concentrations are posing a challenge to all analytical methods. 9 
LSD can only be detected in blood up to 8 h after administration due to serum concentrations in 10 
low ng/ml range. 2-oxo-3-hydroxy LSD (O-H-LSD) is the main metabolite present in urine at 11 
concentrations 16-34 times higher than LSD [3,4]. To our knowledge O-H-LSD has only been 12 
detected once in blood in a postmortem case [5]. According to Li et al. and Klette et al. LSD and 13 
O-H-LSD were regarded as stable under storage conditions of -20°C [6,7]. 14 
Most published methods for LSD detection use either GC-MS or LC-MS/MS with a single stage 15 
quadrupole [8,9,5,10-12,4]. The aim of the present study was to develop a turboflow LC-MS/MS 16 
method with the purpose of rapid quantification of LSD and its main metabolite in serum and 17 
urine in emergency toxicological cases without time consuming extraction steps.  18 
The method was developed using  an ion trap LC-MS/MS instrument in selected reaction 19 
monitoring (SRM) mode after atmospheric pressure ionization (APCI) for the quantification of 20 
LSD and O-H-LSD in urine and serum samples. Poch et al. used a similar APCI LC-MS/MS ion 21 
trap instrument, but mainly for the detection of O-H-LSD [3].  22 
Favretto et al. improved the method, but switched to electrospray ionization for suitable analysis 23 
of LSD and O-H-LSD in blood, urine and vitreous humor [13]. Our method was established and 24 
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successfully applied in five emergency toxicological cases with a suspected LSD intoxication. 1 
Additionally, the method will be used for the analysis of both blood and urine samples from a 2 
double-blind, placebo-controlled clinical trial.  3 
  4 
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Materials and methods 1 
Chemicals and reagents 2 
HPLC grade purity acetonitrile, acetone, methanol, 2-propanol, formic acid and acetic acid were 3 
all purchased from Merck (Darmstadt, Germany).  Ammonium acetate and ammonium carbonate 4 
were obtained in HPLC grade from Merck (Darmstadt, Germany). Distilled water was obtained 5 
from an in-house installed purifier (ELGA, Bucks, United Kingdom).  6 
Drug free serum lyophilisate and urine negative control as blank matrices were obtained from Bio 7 
Rad Laboratories (Irvine, CA, United States). LSD and LSD-d3 were obtained from Lipomed 8 
(Arlesheim, Switzerland) and 2-oxo-3-hydroxy LSD (O-H-LSD) from Cerilliant (Round Rock, 9 
TX, United States).  10 
 11 
LC-MS Analysis 12 
Equipment 13 
The sample extraction system  (Transcend TLX1 HPLC, Thermo Scientific, Basel Switzerland) 14 
consisted of a Thermo PAL autosampler and two Accela 600 pumps as eluting and loading 15 
pumps. The Autosampler and the sample extraction system were all controlled by Aria software 16 
(version 1.6.3) from Thermo Scientific (Basel, Switzerland). A cyclone and a C18XL turboflow 17 
column (Thermo Scientific, Basel Switzerland) for extraction, and a 3 µm Betasyl/Phenyl/Hexyl 18 
column (Thermo Scientific, Basel, Switzerland) for chromatographic separation were used.  19 
The online extraction system was coupled to a LTQ XL mass spectrometer from Thermo 20 
Scientific (Basel, Switzerland) using atmospheric pressure ionization (APCI) , due to its 21 
performance regarding matrix effects [14,15]. 22 
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For the instrument control the corresponding software package consisting of LTQ (v.2.6) for ion 1 
detection, Xcalibur (v.2.1.0) for method programming, and LC-Quan (v.2.6.1) for quantification 2 
(all Thermo Scientific, Basel, Switzerland), was used.  3 
 4 
LC Method 5 
The method was based on a previously published method [16]. Four mobile phases were used in 6 
gradient mode. For extraction, loading B consisted of 10 mM ammonium carbonate in water, 7 
eluting A was 5 mM ammonium acetate in water containing 0.10% formic acid and eluting B 5 8 
mM ammonium acetate in methanol containing 0.50% formic acid, respectively.   9 
Loading B was used as alkaline loading buffer, eluting A and B for chromatographic separation. 10 
Loading and Eluting C (acetonitrile /acetone/2-propanol, 1:1:1 (V/V/V) were used to clean the 11 
extracting and the analytical columns. 12 
The gradient system with a total run time of 12 min is depicted in Table 1. Under the following 13 
gradient conditions LSD and LSD-D3 showed a retention time  of 7.63 min, O-H-LSD  a 14 
retention time of 6.34 min.  15 
MS Conditions 16 
For the quantification of LSD and its metabolite, APCI was used as the ionization source in 17 
positive ion mode. Discharge current and discharge voltage were set to 5µA and. 4.2kV, 18 
respectively. The vaporizer temperature was optimized to 452°C whereas sheath and auxiliary 19 
gas provided best results with flow rates of 40 and 20 arbitrary units (AU). The capillary 20 
temperature was set to 275°C. 21 
LSD and O-H-LSD were quantified using single reaction monitoring (SRM) of the corresponding 22 
mass transitions (LSD m/z 324.6  223.23, O-H-LSD m/z 356.33  338.33, LSD-d3 327.21 23 




Standard solutions 2 
LSD and LSD-D3 were bought as 1mg/ml reference standards in acetonitrile, O-H-LSD as 0.1 3 
mg/ml reference standard in acetonitrile. Stock solutions in acetonitrile containing 100’000 4 
ng/mlLSD, LSD-d3 or 10’000 ng/ml O-H-LSD, respectively, were prepared in duplicate and 5 
stored at -20°C in order to have different sets for quality control (QC) and calibration samples, 6 
respectively. Working solutions of each analyte at 1’000 ng/ml, 100 ng/ml, 10 ng/ml and 1 ng/ml 7 
in water were used for the preparation of QC and calibration samples as well as for matrix and 8 
selectivity experiments. 9 
 10 
Sample preparation 11 
To 100 µl of serum, 100 µl acetonitrile for protein precipitation and 10 µl of a LSD-d3 internal 12 
standard solution (100 ng/ml) were added. An identical volume of urine was diluted with 50 µl of 13 
an ammonium acetate buffer (50mM, pH4) and 10 µl of the internal standard solution. The 14 
samples were then vigorously vortexed, centrifuged for 10 minutes at 13’200 g and the 15 
supernatant afterwards transferred into autosampler vials. 16 
 17 
Calibration 18 
Calibration curve in serum was realized by spiking serum samples with LSD and O-H-LSD to 19 
concentrations of 0.10 ng/ml, 0.25 ng/ml, 0.50 ng/ml, 0.75 ng/ml, 1 ng/ml, 2.50 ng/ml, 5 ng/ml, 20 
7.50 ng/ml and 10 ng/ml plus a blank (matrix only) and zero sample (matrix plus internal 21 
standard). The highest calibration point in serum was adopted from the maximum plasma 22 
concentration out of available i.v. kinetic data [17]. 23 
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The calibration curve in urine was realized by spiking urine samples with O-H-LSD to 1 
concentrations of 1.50 ng/ml, 5 ng/ml, 10 ng/ml, 25 ng/ml, 50 ng/ml, 100 ng/ml, 125 ng/ml, 250 2 
ng/ml and 500 ng/ml. LSD concentrations were  0.10 ng/ml, 0.50 ng/ml, 1 ng/ml, 2 ng/ml, 5 3 
ng/ml, 10 ng/ml, 12 ng/ml, 25 ng/ml, 50 ng/ml, respectively. The highest calibrator in urine was 4 
adopted from published data containing various analyzed urine samples [4].  5 
Both calibration curves were fitted linearily using a weighting factor (1/x2). 6 
In order to demonstrate accuracy and precision of the method 5 QC’s in urine and 6 QC’s in 7 
serum were used with every run. The concentrations of the QC samples can be seen in Table 2 8 
and 3. 9 
 10 
Selectivity 11 
Following the FDA validation guidelines [18], six urine and six serum samples from different 12 
patients and healthy volunteers were collected and analyzed to establish selectivity and check for 13 
unwanted interferences within both matrices. 14 
 15 
Matrix effects and recovery 16 
Matrix effects, recovery and process efficiency were measured and calculated according to 17 
Matuszewski et al [19]. Matrix effects in urine and serum were calculated as ratio of the peak 18 
area before extraction and divided by the peak area after extraction. In contrast to Matuszewski et 19 
al., the extraction step consisted of simple protein precipitation as bypassing the extraction step 20 
on our ion trap system was not possible. Six serum and six urine samples were spiked once with 21 
LSD and O-H-LSD before and after extraction. The peak areas of the spiked samples were then 22 
compared with the area of the spiked mobile phase. Urine samples were spiked to 25 ng/ml LSD 23 
resp. 250 ng/ml O-H-LSD, serum samples to 10 ng/ml each.  Recovery values were calculated as 24 
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areas of standards spiked before extraction divided by the areas of standards spiked after 1 
extraction.  The process efficiency was also adopted from Matuszewsky et al. and calculated as 2 
ration between the area of the standard spiked before extraction, and the areas of the standard in 3 




Limit of quantification 8 
Drug free serum and urine samples were spiked with different concentrations of LSD and O-H-9 
LSD for the determination of the lower limit of quantification (LLOQ). The parent substance and 10 
metabolite ratio was determined 1:1 in serum and assumed 1:10 in urine samples [4]. The LLOQ 11 
concentrations had to give a response at least 5-times greater than the blank. Additionally 12 
precision had to be <20% and the accuracy between 80-120% using at least 5 determinations per 13 
matrix and concentration.  14 
 15 
Carryover 16 
Carryover was determined by quantification of different blanks, running between patient samples, 17 
calibrations and quality controls. 18 
 19 
Reproducibility 20 
According to the FDA guidelines a minimum of five determinations per concentration are 21 
recommended for determination of precision and accuracy [18]. 22 
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The reproducibility of quantification was determined by measuring serum (n=6) and urine (n=5) 1 
quality controls (QC) once on one day (intraday precision and accuracy) and on 6 different days ( 2 
interday precision and accuracy). All values had to fulfill the criteria of a variation coefficient 3 
(CV) below 15%, resp. below 20% at the LLOQ and accuracy between 80-120%. For serum 6 4 
quality controls from LLOQ to the highest calibrator (0.10 ng/ml, 0.40 ng/ml, 0.80 ng/ml, 4 5 
ng/ml, 8ng/ml, 10 ng/ml) were measured once a day. For validation in urine 5 QCs from 1.5 6 
ng/ml to 333 ng/ml were used. 7 
 8 
 9 





None of the blank urine or serum samples showed any interference within the measured mass 3 
range and time frame.  4 
 5 
Matrix effects and recovery 6 
The matrix effects in urine were 138% for LSD and 122% for O-H-LSD. Recovery in urine was 7 
calculated to be 90.00% and 87.80%, respectively. Process efficiency in urine was 124% for LSD 8 
and 107% for O-H-LSD. Serum showed higher matrix effects with 128% for LSD and 78.70% 9 
for O-H-LSD. Recovery in serum was 64.00% for LSD and 32.00%, for O-H-LSD. The Process 10 
efficiencies in serum were calculated to be 128% for LSD and 79% for O-H-LSD. No ion 11 
suppression was found for LSD or O-H-LSD in serum and urine, but as mentioned by Johansen 12 
and Jensen[10] LSD-D3 would correct for any ion suppression. In various negative samples small 13 
LSD concentrations below the LLOQ could be identified which derived from the deuterated 14 
internal standard.  Following these findings, LSD-D3 was measured 10-times at different 15 
concentrations. The working solution of the standard (100ng/ml) contained 0.12% undeuterated 16 
LSD.  This impurity in the peak area of LSD was subtracted from all calibrators, quality controls 17 





Lower limits of quantification 2 
The lowest accurate and precisely measurable concentration was 0.10 ng/ml and thereby 3 
determined as LLOQfor LSD and O-H-LSD in serum. In urine samples the LLOQwas 4 
determined at 0.10 ng/ml for LSD and 1.50 ng/ml for O-H-LSD.  5 
Carryover 6 
No carryover was found for LSD and O-H-LSD in serum samples. In contrast, a slight carryover 7 
(0.10%) was found for O-H-LSD in urine samples following the highest QC (333ng/ml) and the 8 
highest calibration (500ng/ml) in urine. As a consequence, a second consecutive blank was 9 
inserted between and the carryover was reduced to 0.01%. 10 
 11 
Reproducibility 12 
. Calibration curves in urine were linear for both substances,LSD and O-H-LSD with R2 greater 13 
than 0.98. Mean intraday accuracy and precision in serum were 97.40% resp. 5.89% for LSD and 14 
107% resp.4.70% for O-H-LSD (see Table 2). Mean interday accuracy and precision for LSD and 15 
O-H-LSD were 101% resp.6.56% and 99.80% resp.8.35%, respectively (see Table 3).  16 
 17 




LSD and O-H-LSD calibration curves in serum were linear over the range from 0.10 ng/ml to 2 
10ng/ml with a mean correlation coefficient (R2) of 99.86%. The calibration curves of the mean 3 
values is shown in figure 1. Error bars indicate the standard error of the mean. 4 
Calibration curves of LSD and O-H-LSD in urine were linear over the concentration range from 5 
1.50 ng/ml to 333 ng/ml. R2 was found to be 99.93%. The detailed calibration curve is shown in 6 
figure 2. 7 
 8 
Toxicological cases 9 
In the period from January to September 2014, five patients were admitted to the emergency 10 
department (ED) of the University Hospital Basel with suspected LSD intoxication. In all five 11 
cases LSD consumption could be confirmed. Routinely a LC-MS/MS method screening over 700 12 
substances in serum was run to detect the intake of other medication and designer drugs. 13 
As a summary all in-vivo measured concentrations in the matrices available from the emergency 14 
departement can be found in table 4. 15 
 16 
Case 1 17 
A 17-year old girl was brought to the ED with acute confusion and loss of sense of time and 18 
orientation. She admitted consumption of two sugar cubes and one blot with LSD (estimated 19 
dose: 750 µg). A plasma sample for drug screening was taken approximately 3 h after ingestion. 20 
The patient was under chronic treatment with trazodone for depression. An additional LC-21 
MS/MS screen in serum showed the presence of THC and trazodone. Quantification of LSD 22 
revealed a level of 14.70 ng/ml and a quantifiable O-H-LSD level of 0.99 ng/ml in serum. .The 23 
only other published case where O-H-LSD could be detected in blood so far, was in a reanalyzed 24 
13 
 
fatal case 10 years after collection [Chung, 2009 #7]. Figure 3 shows the chromatogram of LSD, 1 
LSD-D3 and O-H-LSD in the serum of this patient. 2 
 3 
Case 2 4 
A 17-year-old male, was brought by the ambulance to the ED with thoracic pressure, restlessness, 5 
and dyspnea. He admitted the intake of one sugar cube with LSD (estimated dose 250µg) at 8 pm 6 
with concomitant consumption of cannabis. He reported onset of the symptoms at 10 pm, 2 hours 7 
post-consumption. In the emergency department the patient was treated with lorazepam and 8 
acetaminophen. Serum analysis revealed a LSD concentration of 1.80 ng/ml in a blood sample 9 
taken at 11 pm.  Case 3 10 
A 21-year-old male was admitted to the ED by ambulance and the police because of aggressive 11 
and uncooperative behavior after consumption of an alleged LSD blot. No information about the 12 
timepoint of the LSD ingestion was available from anamnesis. Serum analysis showed an LSD 13 
concentration of 6.10 ng/ml and an O-H-LSD concentration of 0.45 ng/ml. An additional LC-14 
MS/MS screening revealed the presence of THC, cocaine, and amphetamine.  15 
 16 
Case 4 17 
A 45-year- old male presented himself to the ED with agitation, disorientation, and intense visual 18 
hallucinations. He was partying for two days and consumed alcohol, LSD, cocaine, and cannabis. 19 
The time-point of the LSD intake was not reported. The LC-MS/MS screening confirmed the 20 
intake of THC and cocaine. Quantification of the serum LSD level detected 4.10 ng/ml LSD, but 21 
no quantifiable O-H-LSD.  22 
 23 
Case 5 24 
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A 36-year-old male presented himself to the ED with tactile and visual hallucinations after 1 
consumption of an alcoholic beverage in a club. He suspected someone to have mixed some 2 
drugs in his drink.A screening for LSD in urine revealed 1.30 ng/ml LSD and 9.70 ng/ml O-H-3 
LSD, respectively. An additional LC-MS/MS screening in urine confirmed the presence of THC. 4 
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Discussion & Conclusion 1 
The development of a sensitive method for the measurement of LSD and its metabolite is an 2 
analytical challenge due to its low concentrations in serum and urine.   3 
Purification procedures with solid-phase or liquid-liquid extraction can certainly ead to better 4 
sensitivity of the LC-MS/MS method, but form a time consuming procedure [5]. The short run 5 
time of 12 minutes was mainly given by retention times of LSD, LSD-D3 and O-H-LSD. The 6 
additional time following the LSD and LSD-D3 peak was necessary to ensure clean peak 7 
separation and flushing the columns to minimize carryover. 8 
 Our purpose was to establish a fast and reliable method for application in emergency 9 
toxicological cases where time is crucial. With a short method run of 12 min and minimum 10 
sample preparation, results will be more quickly available so that a fast diagnosis is possible. The 11 
method was applied in five toxicology cases where consumption of LSD could be confirmed four 12 
times in serum and once in urine.  13 
Due to the fast method and obviation of purification steps, a slight loss in sensitivity was 14 
accepted. LLOQ and LOD in serum were hence higher than in other comparable methods 15 
[8,9,5,13,10]. Some showed LOQ’s as low as 0.02 ng/ml for LSD but needed sample preparation 16 
and a longer run time [5]. In contrast, our method was mainly developed to rapidly detect levels 17 
of LSD that occur during acute intoxication. The range of expected LSD concentrations in serum 18 
was difficult to determine because only few pharmacokinetic data is available. In fact, only one 19 
pharmacokinetic study with controlled administration of LSD exists. In this study, peak plasma 20 
concentrations of LSD were 4-6 ng/ml 1-2 hours after administration of LSD  (intravenously at 2 21 
µg/kg) [17]. Therefore we chose 10ng/ml as highest calibrator to cover typically used oral doses 22 
of LSD (100-400 µg) [1]. However, one case was found with a LSD concentration of 14 ng/ml in 23 
plasma among the intoxication cases presented here.  24 
16 
 
This sample had to be diluted (1:1 with distilled water) in order to determine the correct result. 1 
Expected urine concentrations and the calibration range was established considering already 2 
published data [3,4]. Our method fulfilled all criteria for measurement of emergency 3 
toxicological cases. All four cases showed concentrations of LSD in serum in the range of 1.80 – 4 
14.70 ng/ml. Additionally, to our knowledge for the first time we describe the quantification of 5 
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Figure legends 1 
2 
 Fig.1 shows the mean calibration curve of LSD in serum from the validation measurements, The 3 











































Fig.2 shows the mean calibration curve of 2-oxo-3-hydroxy LSD in urine from the validation 2 
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Fig.3 Chromatogram and the respective structural formulas of LSD, LSD-D3 and 2-oxo-3-1 
hydroxy LSD in the serum sample of patient 1 2 
 3 
